UPC_CoA_464/2024

A SYSTEM COMPRISING A PROSTHETIC VALVE AND A DELIVERY CATHETER

AppealsMain AppealCourt of AppealAppealCase Closed

Overview Decisions Citations Documents Timeline

Parties

Claimants

Edwards Lifesciences Corporation(Edwards Lifesciences Group)

Reps: Boris Kreye (Bird & Bird); Anika Boche (Bird & Bird)

Respondents

Meril Italy S.r.l.(Meril Group)
Meril GmbH(Meril Group)
Meril Life Sciences Pvt Ltd.(Meril Group)

Reps: Andreas von Falck (Hogan Lovells International LLP); Roman Würtenberger (Hogan Lovells International LLP); Beatrice Wilden (Hogan Lovells International LLP)

Judges

Klaus Grabinski
Peter Blok
Emmanuel Gougé
Elisabetta Papa
Max Tilmann

Patents

EP3646825
EP 3 646 825

CPC codes: A61F2220/0075, A61F2/2436, A61F2250/0065, A61F2/2418, A61F2230/0054, A61F2250/0069, A61F2/2433

Sector: Pharmaceutical & Medical

Outcome

Patent maintained

Filed: Aug 2, 2024

First decided: Nov 25, 2025

Language: English

The Court of Appeal dismissed the Meril companies' appeals against the revocation and counterclaim revocation decisions and Edwards' appeal against the infringement decision, upholding the patent EP 3 646 825 (heart valve). Key rulings: (I–VIII) All revocation and counterclaim appeals rejected; Meril bears 60% of Edwards' costs in the revocation proceedings and Edwards bears 40% of Meril's costs. (IX–X) The infringement decision was partially set aside: the injunction and preliminary damages order do not extend to XL devices (30.5mm and 32mm) that had not been scheduled for implantation in a patient by 15 November 2024. Preliminary damages reduced to not exceed €363,000 for Meril India and Meril Germany. The value of the proceedings is €8,000,000.

Open on UPC Registry

Claims

At issueall

Maintainedall

Infringedall

Notes: Court of Appeal upheld validity of EP 3 646 825 and confirmed infringement by Meril (excluding XL devices not scheduled before 15 Nov 2024); appeals against revocation dismissed.